Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial

K. Shivkumar, S. M. Jafri*, M. Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations

Abstract

Nonvalvular atrial fibrillation is common and is associated with a high risk of systemic embolism. Recently, several large randomized trials have been completed that have established the efficacy of antithrombotic therapy for both primary and secondary prevention of systemic thromboembolism with an acceptable rate of bleeding complications in these patients. This section of clinical trials review summarizes data from all published randomized trials of antithrombotic therapy in atrial fibrillation. The efficacy of aspirin versus warfarin is analyzed. The role of clinical and echocardiographic findings to stratify patients is also highlighted. The Stroke Prevention in Atrial Fibrillation II trial is discussed in detail.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalProgress in Cardiovascular Diseases
Volume38
Issue number4
DOIs
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial'. Together they form a unique fingerprint.

Cite this